Metastatic Malignant Neoplasm in the Brain Clinical Trial
Official title:
Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors
Verified date | December 2019 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with brain tumors. Comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.
Status | Completed |
Enrollment | 9 |
Est. completion date | January 21, 2019 |
Est. primary completion date | January 21, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Have a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or metastatic) by standard clinical diagnosis such as pathology or imaging - Planned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combined Exclusion Criteria: - Inability to provide informed consent - Pregnancy - Inability to lie still for the imaging study - Weight over 350 lbs. |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage Change in Measure of FLT Flux | The percentage change in the kinetic model parameter of FLT flux (Ki) was recorded. Ki is estimated from parameters derived by fitting the FLT input function and the total blood activity curve to the tissue time-activity curve data. | Baseline to up to 1 year after completion of treatment | |
Primary | Percentage Change in Measure of Reflecting Transport | The percentage change in the kinetic model parameter of FLT transport (K1) was recorded. K1 is defined as the transfer of FLT from blood into tissue (tumor). | Baseline to up to 1 year after completion of treatment | |
Primary | Percentage Change in Measure of Standard Uptake Value | The percentage change in the maximum standard uptake value (SUVmax) was recorded. SUVmax is defined as the amount of FLT uptake in a lesion. | Baseline to up to 1 year after completion of treatment | |
Primary | Survival | Time from study entry to death will be recorded | Up to 7 years | |
Primary | Clinical Response Assessed Using Revised Assessment in Neuro-Oncology Criteria | This is clinical response as assessed at physician discretion using standard of care criteria. | Up to 7 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04062305 -
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
|
N/A | |
Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT03071913 -
Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
|
||
Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
Recruiting |
NCT03270059 -
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
|
Phase 2 | |
Terminated |
NCT00096265 -
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
Active, not recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05341349 -
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases
|
Phase 1 | |
Active, not recruiting |
NCT04114981 -
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
|
Phase 3 | |
Recruiting |
NCT03741673 -
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
|
Phase 3 | |
Completed |
NCT03680144 -
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
|
N/A | |
Recruiting |
NCT03750227 -
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
|
Phase 3 | |
Terminated |
NCT00659126 -
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
|
Phase 2 | |
Recruiting |
NCT03418961 -
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02993146 -
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
|
Phase 1 | |
Not yet recruiting |
NCT06328686 -
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
|
Early Phase 1 | |
Active, not recruiting |
NCT02589522 -
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
|
Phase 1 | |
Recruiting |
NCT04804644 -
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
|
Phase 3 | |
Withdrawn |
NCT03868423 -
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
|
Phase 2 |